ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1Genealiases: CENTD2 · cnt-d2
Q-omics provides the consensus-scored ARAP1 profile across patient tissues and cancer cell-line models. ARAP1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ARAP1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ARAP1 protein abundance shows 26,024 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where ARAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARAP1 survival associations across molecular data types. ARAP1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARAP1 RNA expression–survival associations across cancer types. High ARAP1 expression shows unfavorable associations in UVM, LIHC, ACC and LAML, but favorable associations in KIRC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ARAP1 RNA expression.
This table summarizes ARAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARAP1 shows lower tumor expression in LUAD and higher tumor expression in KIRC, LIHC, HNSC, KICH and STAD. The KIRC box plot shows higher ARAP1 RNA expression in tumor versus normal tissue (log2 FC = +0.652, t-test p < 0.001).
This table shows molecular features associated with ARAP1 in patient tissues and cancer cell lines. In patient samples, ARAP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
